Over the past several years, the pharmaceutical industry has witnessed significant growth in the biologics sector, with biologics representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.
In reality though, the impact of biosimilar entry is not necessarily purely economic. Due to the myriad forms of intellectual property incorporated into many biologics—proprietary cell lines, formulation processes and the like—a biosimilar is just that: similar, but not identical, to the branded product it hopes to supplant. The salient question to ask of any potential biosimilar entrant is this: Just how similar is similar?
Download to Learn More.